Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been...
Neuroscience
Dominari Holdings Issues Letter to Shareholders
NEW YORK, June 4, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) today issued the following letter to shareholders: ...
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to...
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers...
Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property...
Matter Neuroscience announces collaboration with Stanford Medicine combining Matter protocol with real-time fMRI neurofeedback to support emotion-based interventions in depression
This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks...
Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes
Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases and drug discovery TOKYO, June...
Listening to Lives Behind the Numbers: Linus Health Study Champions Person-Centered Brain Health Assessments
Peer-reviewed journal article highlights need for personalized, culturally relevant approaches to cognitive care and research BOSTON, June 2, 2025 /PRNewswire/...
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic...
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)...
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about...
NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is...
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom...
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani...
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025...